Overview

A Crossover Safety Study of Ferumoxytol Versus Placebo

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
Phase:
Phase 3
Details
Lead Sponsor:
AMAG Pharmaceuticals, Inc.
Treatments:
Ferrosoferric Oxide